(Q37705396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

HER2 as a target for breast cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Andrea Balsari

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Serenella M Pupa

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Manuela Campiglio

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

711-724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20214497%20AND%20SRC:MED&resulttype=core&format=json

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Biologic and therapeutic role of HER2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

HER2 as a prognostic factor in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Prognostic and predictive value of HER2/neu oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Role of HER2 gene overexpression in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

The early relapse of premenopausal patients after surgery for node-positive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Role of HER2 in wound-induced breast carcinoma proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Role of proliferation in HER2 status predicted response to doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Third consensus on medical treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Vaccine immunotherapy in breast cancer treatment: promising, but still early.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Use of tumour-responsive T cells as cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Prophylactic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Vaccines for tumour prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Role of HER2/neu in tumor progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003689972